Expert Opinion on Emerging Drugs最新文献

Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms. 新出现的酪氨酸激酶抑制剂用于治疗神经内分泌肿瘤。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-05-29 DOI: 10.1080/14728214.2025.2508994

Nicola Fazio, Anna La Salvia

{"title":"Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms.","authors":"Nicola Fazio, Anna La Salvia","doi":"10.1080/14728214.2025.2508994","DOIUrl":"https://doi.org/10.1080/14728214.2025.2508994","url":null,"abstract":"Introduction: In the era of precision medicine, a molecularly targeted therapeutical approach is still missing in the field of neuroendocrine neoplasms (NENs) other than for radioligand therapy (RLT). So far sunitinib is the only tyrosine kinase inhibitor (TKI) available in clinical practice for NENs in Western countries, limited to advanced, progressing pancreatic neuroendocrine tumors (NETs). A few TKIs worldwide reached an advanced stage of clinical investigation with promising results.Areas covered: This narrative review is an updated analysis about the status of TKIs in the most advanced stage of clinical investigation in NENs. Our work is focused specifically on a critical analysis of TKIs investigated in phase III clinical trials, such as Axitinib, Surufatinib and Cabozantinib.Expert opinion: The Expert Opinion section of our manuscript is a critical overview of the results coming from phase II and III clinical trials with Axitinib, Surufatinib and Cabozantinib, and, it is mainly centered on strategies of investigation of these TKIs, including geographical areas and indirect comparison about study design.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers. 针对肿瘤相关巨噬细胞治疗实体器官癌的新疗法。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-05-25 DOI: 10.1080/14728214.2025.2504376

Dandan Li, Udo Rudloff

{"title":"Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.","authors":"Dandan Li, Udo Rudloff","doi":"10.1080/14728214.2025.2504376","DOIUrl":"10.1080/14728214.2025.2504376","url":null,"abstract":"Introduction: Over the last decade, immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 or CTLA-4, which reinvigorate T cells for tumor control have become standard-of-care treatment options. In response to the increasingly recognized mechanisms of resistance to T cell activation in immunologically cold tumors, immuno-oncology drug development has started to shift beyond T cell approaches. These include tumor-associated macrophages (TAMs), a major pro-tumor immune cell population in the tumor microenvironment known to silence immune responses.Areas covered: Here we outline anti-TAM therapies in current development, either as monotherapy or in combination with other treatment modalities. We describe emerging drugs targeting TAMs under investigation in phase II and III testing with a focus on their distinguishing mechanism of action which include (1) reprogramming of TAMs toward anti-tumor function and immune surveillance, (2) blockade of recruitment, and (3) reduction and ablation of TAMs.Expert opinion: Several new immuno-oncology agents are under investigation to harness anti-tumor functions of TAMs. While robust anti-tumor efficacy of anti-TAM therapies across advanced solid organ cancers remains elusive to-date, TAM reprogramming therapies have yielded benefits in select cancers. The inherent heterogeneity of the diverse TAM population will require enhanced investments into biomarker-driven approaches to fully leverage its therapeutic potential.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-39"},"PeriodicalIF":2.7,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being. 探索裸盖菇素在心理健康和姑息医学中的作用：改善幸福感的途径。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-04-10 DOI: 10.1080/14728214.2025.2488786

Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero, Lina-Maria Castro, Veronica Paez, Seetal Dodd, Rosa-Helena Bustos

{"title":"Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.","authors":"Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero, Lina-Maria Castro, Veronica Paez, Seetal Dodd, Rosa-Helena Bustos","doi":"10.1080/14728214.2025.2488786","DOIUrl":"10.1080/14728214.2025.2488786","url":null,"abstract":"Introduction: Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care.Areas covered: Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult psychiatry and palliative care are the medical fields that show the greatest interest in psilocybin treatment.Expert opinion: Psilocybin is a powerful drug that needs to be used with caution but may benefit some patients, including when other options have failed. It is best evidenced in treatment resistant depression and in palliative care, where patients are usually treated in specialist care centers. It has a novel mechanism of action, targeting the 5HT2A receptor, and can show rapid onset of action. There are many questions regarding its use that remain to be clarified, including its efficacy for other indications and its role as adjunctive treatment in psychotherapy. The psychoactive, or psychedelic effects are well documented, but their clinical importance is disputed.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and limitations of mesenchymal stem cell therapy for lung diseases in clinical trials. 临床试验中间充质干细胞治疗肺部疾病的挑战和局限性。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-04-07 DOI: 10.1080/14728214.2025.2489700

Mayck Medeiros Amaral da Silva, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz

引用次数: 0

An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer's disease: the role of apolipoprotein E. 治疗阿尔茨海默病的新型抗淀粉样蛋白-β单克隆抗体的最新进展：脂蛋白E的作用。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-03-26 DOI: 10.1080/14728214.2025.2481847

Madia Lozupone, Vittorio Dibello, Antonio Daniele, Francesco Panza

引用次数: 0

Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder. 新出现的免疫耐受疗法治疗视神经脊髓炎。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-02-23 DOI: 10.1080/14728214.2025.2470706

Edgar Carnero Contentti, Jorge Correale

引用次数: 0

Emerging treatments for sarcoma: from 2024 onward. 肉瘤的新疗法：从2024年开始。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-02-03 DOI: 10.1080/14728214.2025.2460525

Diego Gómez-Puerto, Carlo M Cicala, Claudia Valverde, César Serrano

{"title":"Emerging treatments for sarcoma: from 2024 onward.","authors":"Diego Gómez-Puerto, Carlo M Cicala, Claudia Valverde, César Serrano","doi":"10.1080/14728214.2025.2460525","DOIUrl":"10.1080/14728214.2025.2460525","url":null,"abstract":"Introduction: Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized diseases, surgery and radiotherapy remain the cornerstone treatments. However, systemic options for advanced stages are limited, with an overall survival of approximately 20 months. There is an urgent need to refine clinical trial designs and evaluate novel therapies to improve patient outcomes.Areas covered: This review summarizes recent advancements in sarcoma clinical trials, highlighting promising therapies that may reshape treatment paradigms. It also examines insights from comprehensive genomic profiling studies, which are paving the way for next-generation therapeutic approaches.Expert opinion: The heterogeneity and rarity of sarcomas present substantial challenges to the development and regulatory approval of effective therapies. Recent progress in the field has introduced innovative approaches, including novel chemotherapeutic agents, targeted therapies, and immunotherapeutics. However, despite these advancements, significant hurdles persist. While these strategies have demonstrated some success, the overall improvements in survival have often been modest, irrespective of the therapeutic modality. This underscores critical concerns regarding the true cost-benefit balance and the potential for adverse effects, particularly when evaluated over extended follow-up periods.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-18"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging biological treatments for asthma. 新兴的哮喘生物疗法。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-02-01 DOI: 10.1080/14728214.2025.2460529

Daniela Pastore, Chiara Lupia, Maria D'Amato, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Luca Gallelli, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia

{"title":"Emerging biological treatments for asthma.","authors":"Daniela Pastore, Chiara Lupia, Maria D'Amato, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Luca Gallelli, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia","doi":"10.1080/14728214.2025.2460529","DOIUrl":"10.1080/14728214.2025.2460529","url":null,"abstract":"Introduction: Severe asthma is a chronic airway disease characterized by many pathomechanisms known as endotypes. Biological therapies targeting severe asthma endotypes have significantly improved the treatment of this disease, thus remarkably bettering patient quality of life.Areas covered: This review aims to describe current biological therapies for severe asthma, highlighting emerging ones. Several studies have confirmed the beneficial effects of currently available monoclonal antibodies targeting immunoglobulin E (IgE), interleukin-5 (IL-5) or its receptor, and interleukin-4 (IL-4)/interleukin-13 (IL-13) receptors (IL-4R/IL-13R). However, patients with T2-low asthma are not eligible for the above biological therapies.Expert opinion: New treatments are now moving toward targeting the upstream pathways of asthma pathogenesis, coordinated by innate cytokines such as alarmins. These key proinflammatory mediators orchestrate the activation of complex cellular networks including both innate and adaptive immune responses. Alarmins include thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33), which are released from injured airway epithelial cells. TSLP and the other alarmins are suitable targets of biological therapies which are effective for add-on treatment of type 2 asthma. Moreover, anti-alarmin monoclonal antibodies can be also beneficial for patients with T2-low, poorly controlled severe asthma.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitapivat: a step forward across different hemolytic diseases. 米他伐：跨越不同溶血疾病的一个进步。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-01-29 DOI: 10.1080/14728214.2025.2458063

Mohammad Hassan Hodroj, Joseph Klim, Nicole Charbel, Ali Taher

引用次数: 0

FcRn inhibitors in the context of myasthenia gravis. FcRn抑制剂在重症肌无力中的作用。

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2025-01-28 DOI: 10.1080/14728214.2025.2458061

Deepak Menon, Vinaya Bhandari

引用次数: 0